A Quick Review of Sansure at Medlab 2024
As the healthcare industry gears up for one of the most anticipated events of the year, Medlab 2024 aims to provide groundbreaking innovations and cutting-edge technology. From February 5th to 8th, 2024, the Dubai World Trade Centre in Dubai, UAE, transformed into a haven for medical professionals and industry leaders alike.
Located at the crossroads of innovation and necessity, Medlab serves as a catalyst for industry-wide transformation. This year, we, Sansure, a key player in the world of in vitro diagnostic industry, offer diagnostic solutions that are poised to revolutionize the healthcare landscape.
Sansure’s Showcase at Medlab 2024
Sansure serves as a provider of in vitro diagnostic solutions, integrating diagnostic reagents, instruments, and independent clinical laboratory services, all centered around our innovative gene technology. For years, we have been developing our technologies, forging a series of diagnostic products that fit the market demands, helping to resolve community screening and clinical laboratory diagnosis, and relieving the clinical burden by providing rapid and accurate diagnostic results to support treatment decisions. And at Medlab 2024, as one of the Platinum Partners, we presented the potential of diagnostic solutions to attendees.
Sansure’s Exhibits at the Event
1. iPonatic III Portable Molecular Workstation:
The groundbreaking POCT instrument, iPonatic III, is designed to bring molecular diagnostics to the forefront of point-of-care testing. Its compact design and powerful capabilities make it a game-changer in delivering rapid and accurate results.
2. Surelite Automated CLIA System:
Sansure also showcased the Surelite series, an automated Chemiluminescence Immunoassay (CLIA) system. Surelite 8 and Surelite 16 exemplify compact automated CLIA systems, providing swift and accurate diagnostic results in as fast as 15 minutes. Their intelligent design, encompassing an all-in-one cartridge and a comprehensive array of assays, seamlessly aligns with diverse clinical demands, eliminating the need for additional consumables and minimizing waste.
3. Automated Nucleic Acid Extraction System:
Since 2012, Sansure has been at the forefront of advancing automated nucleic acid extraction instruments. In that pivotal year, the company successfully introduced a high-throughput, high-precision, and exceptionally efficient system. This advanced technology enables a smooth workflow encompassing sample preprocessing and nucleic acid extraction, reflecting Sansure’s commitment to innovation in molecular diagnostics.
4. Automated Electrochemiluminescence Analyzer:
YnY 2050 was another exhibit that has won much attention. The YnY 2050 analyzers utilize cutting-edge, fully automated technology with Enhanced ElectroChemiLuminescence (EECL) for immunoassay analysis. The signaling antibody/antigen is labeled with an electronically Neutral Ruthenium Complex (NRC), while the capturing antibody/antigen is coated with magnetic microbeads. When combined with a clinical sample, a sandwich immunocomplex forms on the microbeads, which are then precisely captured in an ElectroChemiLuminescence measuring cell using a movable magnet.
A TPA-containing buffer ensures analysis purity by eliminating undesired substances and creating a favorable chemical environment for NRC units to undergo electrochemical reactions, resulting in a luminescent excited state. The light signal is quantitatively analyzed by a Photomultiplier Tube (PMT).
5. Real-Time Quantitative Thermal Cycler:
The MA-6000 Real-Time Quantitative Thermal Cycler, after years of dedicated research and development, stands as a testament to its worth. This advanced technology promises to enhance patient care and reduce waiting times by processing up to 96 samples simultaneously. Our Real-Time fluorescence quantitative PCR system, MA-6000, features innovative hardware, structure, and optimized software to ensure superior quality results.
Professionals and experts from all around the globe were “allured” by our presentation, being drawn into an insightful discussion on the applications, efficiency, and strengths of our offerings. This provided us with a valuable opportunity to gauge market tendencies and allowed attendees to gain a deeper understanding of Sansure.
Honors, Thanks & Wish
As we reflect on this prestigious event, we express our gratitude to Medlab 2024 for the platform provided to engage with industry leaders and experts. The positive reception and insightful discussions have fueled our enthusiasm to push the boundaries of diagnostic technologies further.
Looking ahead, we are excited about the future possibilities and the impact our solutions can have on the global healthcare landscape. Sansure remains dedicated to advancing genetic technology, bridging gaps in diagnostics, and contributing to the collective efforts to improve patient outcomes. Let’s look forward to the future of IVD.
